Mason Capital Management has gone public with a detailed attack on the board of Grifols, alleging corporate governance failures and what it calls significant shareholder value destruction under the directors currently overseeing the Spanish plasma-derived medicines company.

The activist fund's intervention, distributed via Business Wire, puts the Grifols board on notice that its conduct will now be litigated in front of the company's full shareholder base rather than behind closed doors. Mason Capital's decision to publish its criticisms marks an escalation in a dispute that centres on who bears responsibility for the erosion of value at one of Europe's largest biotechnology businesses.

What does Mason Capital allege?

The fund's central claim is twofold.

• Governance failure. Mason Capital argues the board of directors has not met the standards of oversight that shareholders of a listed company of Grifols' size and complexity are entitled to expect.
• Value destruction. The investor asserts that these governance shortcomings have translated directly into significant destruction of shareholder value, harming the owners of the business rather than only its reputation.

Mason Capital frames the two issues as inseparable: in its telling, weak board oversight is not an abstract governance concern but the mechanism through which investors have lost money. The fund presents its case as a documented record of board decisions and their consequences for equity holders.

Why does this matter for Grifols shareholders?

For a company of Grifols' profile — a global player in plasma-derived therapies with a broad institutional investor base — a public accusation of this kind from an activist fund carries weight beyond a single press release.

Shareholder activism in European large-caps has increasingly shifted from private engagement to public campaigns, and publishing allegations of board-level failure is a standard opening move when an investor concludes that quiet dialogue has run its course. Mason Capital's statement signals that the fund believes shareholders themselves should now judge the board's record.

The accusation also raises the classic accountability question that follows any value-destruction claim: whether the incumbent directors are the right people to lead a recovery, or whether change at board level is the precondition for one.

What could come next?

Public letters of this type typically precede further escalation. An activist fund that has documented governance failures and value destruction in public usually has a specific ask — board seats, a chair replacement, strategic review or a break-up — and Mason Capital's statement positions it to make such demands to the full register of shareholders.

For Grifols' management, the immediate challenge is reputational as much as financial. An allegation that the board destroyed shareholder value invites every institutional investor to re-examine the company's governance record, its board composition and the decisions taken under the current directors.

The company's response — or silence — will now shape the next phase of the confrontation between one of its investors and the directors Mason Capital holds responsible.